Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Galapagos Receives Transparency Notifications from Bank of America

globenewswire.com

Galapagos Receives Transparency Notifications from Bank of America Mechelen, Belgium; March 4, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.

Pursuant to Belgian transparency legislation 1, Galapagos received transparency notifications on February 27 and March 2, 2026, from Bank of America Corporation. The initial notification indicates that Bank of America Corporation, as controlling entity, and its controlled entity, BofA Securities, Inc., individually crossed above the threshold of 5% of Galapagos’ voting rights on February 26, 2026, including exceeding the threshold of 5% for equivalent financial instruments, as a result of an acquisition of Galapagos’ equivalent financial instruments. Subsequently on March 2, Galapagos received a notification indicating that BofA Securities, Inc. fell below the 5% threshold of Galapagos’ voting rights again on February 27, 2026 following the disposal of such instruments.

On March 2, 2026, Bank of America Corporation (taking into account the holding of its affiliates) owned 292,642 voting rights and 3,491,679 equivalent financial instruments, representing together 5.74% of Galapagos’ currently outstanding 65,897,071 shares.

Summary of the transactions:

Content of the notifications from Bank of America Corporation:

The notification dated March 2, 2026, contains the following information:

The chain of control has been described at the end of the notification (section 11) and can be found here.

Content of the notifications from Bank of America Corporation:

The notification dated February 27, 2026, contains the following information:

The chain of control has been described at the end of the notification (section 11) and can be found here.

About Galapagos

Galapagos is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit www.glpg.com or follow us on LinkedIn or X.

For further information, contact Galapagos:

Investor Relations

Glenn Schulman

+1 412 522 6239

ir@glpg.com

Media

Media

Katie Morris

+1 952 288 6821

katiemorris@ententeinc.com

Visit us at www.glpg.com or follow us on LinkedIn or X.

1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.

Attachment